AFIB Acutus Medical

Acutus Medical to Present at the 43rd Annual Canaccord Growth Conference

Acutus Medical to Present at the 43rd Annual Canaccord Growth Conference

CARLSBAD, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 43rd Annual Canaccord Growth Conference on Thursday, August 10, 2023 at 9:30 a.m. Eastern Time at the InterContinental Boston Hotel in Boston, MA.

A live webcast of the presentation may be accessed by visiting ir.acutusmedical.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days.

About Acutus Medical, Inc.

Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Investor Contact

Caroline Corner

ICR Westwicke

D: 415-202-5678

Media Contact

Rhiannon Pickus

442-232-6094



EN
27/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acutus Medical

 PRESS RELEASE

Acutus Medical Reports Full Year 2024 Financial Results

Acutus Medical Reports Full Year 2024 Financial Results CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.Cash, cash equivalents, marketable securities and restri...

 PRESS RELEASE

Acutus Medical Announces Operational Downsizing

Acutus Medical Announces Operational Downsizing CARLSBAD, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and operational downsizing. Dr. Shaden Marzouk, Chairperson of the Board of Directors of Acutus, commented, “Following an extensive strategic review by the Company’s Board of Directors, we are taking the hard but necessary steps to reduce the size of our organization while complying with our remaining obligations to Medtronic for the production of left-heart access products.” Takeo ...

 PRESS RELEASE

Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial R...

Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.Recorded $2.4 million in gain on sale of bus...

 PRESS RELEASE

Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial ...

Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024. Recent Highlights: Second quarter revenue from Continuing Operations of $4.1 million grew 172% year-over-year, from $1.5 million in the same quarter last year.Operating expenses for continuing operations were $2.2 million, a reduction of 47% compared to the same period last year.Recorded $2.9 million in gain on sale of business,...

 PRESS RELEASE

Acutus Medical Reports First Quarter 2024 Financial Results

Acutus Medical Reports First Quarter 2024 Financial Results CARLSBAD, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the first quarter of 2024. Recent Highlights: First quarter revenue from Continuing Operations of $3.6 million grew 192% year-over-year, from $1.2 million in the same quarter last year..Operating expenses for continuing operations were $3.3 million, a reduction of 38% compared to the same period last year.Recorded $2.8 million in gain on sale of business, an increase of 131% compared to ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch